PRINCETON, N.J., June 4, 2008 (PRIME NEWSWIRE) -- Pharmacopeia (Nasdaq:PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that it has identified a new lead compound for advancement in its alliance with GlaxoSmithKline (NYSE:GSK), through its collaboration with the Center of Excellence for External Drug Discovery (CEEDD). This newly identified lead compound is the second from a program being evaluated as a potential treatment for respiratory disease. As a result of this identification, Pharmacopeia received a $500,000 milestone payment from GSK.
